Experts Recommend Use Of Sinovac Covid Vaccine

"); jQuery("#212 h3").html("

Related News Programmes

"); });

2021-02-16 HKT 20:09

Share this story

facebook

  • Experts recommend use of Sinovac Covid vaccine

Experts advising the government on its Covid-19 vaccination programme on Tuesday recommended the emergency use of the Sinovac vaccine in Hong Kong, after receiving data from the mainland drug maker suggesting that its product’s efficacy rate exceeds 60 percent.

The panel’s convenor, Professor Wallace Lau, said the panel unanimously agreed that the vaccine’s efficacy outweighs its possible risks.

He said the panel had received the information it sought following a meeting on the Sinovac jabs last week, and the data provided of late-stage trials show the vaccine’s efficacy rate is 62.3 percent – when two doses are administered 28 days apart.

A previously-reported efficacy rate of barely over 50 percent from late-stage clinical trials in Brazil had raised concerns that the vaccine isn’t as effective as it should be for emergency use.

But Lau told reporters that all the data provided has put those fears to rest.

“This is about an emergency use of a vaccine that will hopefully help to protect the people of Hong Kong from Covid. We have received the data from Sinovac. The data that we have looked at appeared to show that this vaccine is efficacious,” he said.

The World Health Organisation (WHO) has yet to approve the Sinovac vaccine, though Lau said it has met the body’s minimal criteria for emergency use.

The government had last month decided to exempt Sinovac from having to publish clinical data in medical journals, saying they could instead give the information directly to the Hong Kong experts.

Lau said what they received was every bit as good as the data that would have been published – they just did the work themselves.

“When we looked at the data… we have actually used the same attitude as how we normally would peer-review a clinical trial report to be ready for publication in a learned journal. We have gone through all the procedures as needed,” he said.

The expert also waved off suggestions that the government had pressured the panel into recommending the vaccine.

“There is no pressure at all from anyone. Over the last few days, I have more or less shut myself down from all the newspapers etc. We have concentrated primarily on looking at the data,” he said.

Sinovac was supposed to have already delivered a million doses of coronavirus vaccines to Hong Kong by the end of January, but authorities were unable to approve the jabs because of a lack of the necessary data.

A number of countries have ordered Sinovac vaccines, including Turkey, Indonesia and Brazil.

Vaccines produced by the German firm BioNTech remains the only formally approved Covid-19 vaccine in Hong Kong for now.

RECENT NEWS

ZA Bank Brings Nasdaq Data To Hong Kong, Expanding US Stock Access And Investor Education

ZA Bank and Nasdaq have announced a collaboration aimed at enhancing digital wealth management in Hong Kong and interna... Read more

Hong Kong To Study One‑Stop Infrastructure For Equities, Bonds And Digital Assets

The Hong Kong Monetary Authority’s (HKMA) CMU OmniClear and the Hong Kong Exchange (HKEX) are set to begin a study on... Read more

Hong Kong To Issue First Stablecoin Licenses In March, Expand Crypto Regulation

Hong Kong will issue its first licenses for fiat-referenced stablecoin issuers in March and introduce new legislation l... Read more

MSIG Joins US$6B IFC Credit Insurance Facility To Boost Emerging Market Lending

MSIG USA and Mitsui Sumitomo Insurance (MSI Japan), together referred to as MSIG, have joined a new insurance-ba... Read more

Why The $2 Trillion Stablecoin Prediction Is Too Low

McKinsey estimates the stablecoin market will hit $2 trillion by 2028. But according to Sam Lin, COO of dtcpay, even th... Read more

RedotPay Eyes US IPO With Potential US$1 Billion Raise

RedotPay is reportedly exploring an IPO in the US that could raise more than US$1 billion, according to people famili... Read more